prostaglandins

Fixed-combination glaucoma agent yields positive safety, efficacy dataA phase III trial for the fixed-combination netarsudil/latanoprost agent (Roclatan, Aerie Pharmaceuticals)reports positive results. The company plans to submit a NDA for the drug in early 2018.
Assessing the impact of FLACS on surgical outcomesFLACS is related to an increase of anterior chamber prostaglandin and cytokines, resulting in intra-operative miosis. This can be prevented by pre-operative non-steroidal anti-inflammatory drug application. As a result of methodological problems, several studies on the association between femtosecond laser-assisted cataract surgery and cystoid macular oedema are inconclusive.
Oral prostaglandin safer than vaginal for induction?A study in Sweden looked at safety and effectiveness.
Better alternatives to standalone prostaglandin analog therapyPhysicians have the option of various adjunctive therapy when prostaglandin analog therapy alone is not sufficiently potent to lower IOP, i.e., they can add one agent, a fixed-combination therapy, or perform selective laser trabeculoplasty (SLT).
2015's glaucoma therapy advancesWhile no new drug shook up the world of glaucoma in 2015, a variety of promising agents made incremental advances toward the market with their true potential as yet unproven. Manufacturers have continued to refine approaches to existing drugs.
Anterior capsulotomy is the main prostaglandin release inducer in FLACSResearch presented in this article found anterior capsulotomy to be the main trigger for an increase of prostaglandins in aqueous humor immediately after laser-assisted cataract surgery. Optimised energy settings in combination with NSAIDs might therefore help reduce laser-induced miosis.
Changing trends that may alter course of glaucoma practices
Capsulotomy triggers prostaglandin release in FLACSAnterior capsulotomy triggers an increase of prostaglandins in the aqueous humour immediately after FLACS, according to researchers from Ruhr University Eye Hospital, Bochum, Germany.
Rethinking prostaglandin analogs side effectsI recently came across a journal publication describing a patient with Crohn’s disease and open-angle glaucoma.1 Essentially, the patient’s treatment with topical latanoprost was associated with an exacerbation of her Crohn’s disease.
Researchers eye possible PAP link to bimatoprostThe first study attempting to quantify the impact of eyelid application of Latisse (bimatoprost 0.03 percent, Allergan) on periorbital fat is under way, its lead investigator said at the Cosmetic Surgery Forum.